PCVX Q1 2023 Earnings — Vaxcyte, Inc. Revenue & Financial Results | Market Cap Arena

PCVXVaxcyte, Inc.

$9B

Q1 2023 Earnings

Healthcare Biotechnology

Income Statement

Revenue

$0

Gross Profit

$0

Operating Income

-$71M

Net Income

-$60M

EPS (Diluted)

$-0.70

QoQ Revenue Growth

NaN%

Cash Flow

Operating Cash Flow

-$48M

Free Cash Flow

-$53M

Stock-Based Comp.

$10M

Balance Sheet

Total Assets

$1.0B

Total Liabilities

$63M

Stockholders' Equity

$945M

Cash & Equivalents

$380M

Year-over-Year Comparison

Metric	Current	Year Ago	Change
Revenue	$0	$0	—
Gross Profit	$0	$0	—
Operating Income	-$71M	-$39M	-81.5%
Net Income	-$60M	-$39M	-55.1%